Summary : This figure presents an initial pharmacological treatment algorithm for patients with chronic obstructive pulmonary disease (COPD), stratified by exacerbation history and symptom severity, and grouped into A, B, and E for treatment recommendations. flowchart: # Nodes : • "≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization" (rectangle, top left) • "0 or 1 moderate exacerbations (not leading to hospital admission)" (rectangle, bottom left) • "GROUP E: LABA + LAMA* (consider LABA+LAMA+ICS* if blood eos ≥ 300)" (rectangle, top right) • "GROUP A: A bronchodilator" (rectangle, bottom center) • "GROUP B: LABA + LAMA*" (rectangle, bottom right) • "mMRC 0-1, CAT < 10" (rectangle, below GROUP A) • "mMRC ≥ 2, CAT ≥ 10" (rectangle, below GROUP B) # Connectors : • Arrow from "≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization" to "GROUP E: LABA + LAMA*" • Arrow from "0 or 1 moderate exacerbations (not leading to hospital admission)" splits to "GROUP A: A bronchodilator" and "GROUP B: LABA + LAMA*" • "GROUP A: A bronchodilator" is associated with "mMRC 0-1, CAT < 10" • "GROUP B: LABA + LAMA*" is associated with "mMRC ≥ 2, CAT ≥ 10" # Layout : • Two main branches based on exacerbation history (top left and bottom left). • Severe exacerbation branch leads directly to GROUP E (top right). • Mild exacerbation branch splits into GROUP A (center) and GROUP B (right), further differentiated by symptom scores (mMRC and CAT). • Symptom score boxes are placed below their respective treatment groups. # Treatment Recommendations : • GROUP E: LABA + LAMA*; consider LABA+LAMA+ICS* if blood eosinophils ≥ 300. • GROUP A: A bronchodilator. • GROUP B: LABA + LAMA*. • *Note: Single inhaler therapy may be more convenient and effective than multiple inhalers; single inhalers improve adherence to treatment. # Definitions & Criteria : • Exacerbations refer to the number per year. • Blood eosinophil count in cells per microliter. • mMRC: modified Medical Research Council dyspnea questionnaire. • CAT™: COPD Assessment Test™. # Analysis : • The flowchart stratifies COPD patients by exacerbation history and symptom severity (mMRC, CAT). • Patients with frequent or severe exacerbations (≥2 moderate or ≥1 hospitalization) are recommended dual bronchodilator therapy (LABA + LAMA), with possible addition of ICS if eosinophils are high. • Patients with low exacerbation risk are further divided by symptom scores: those with low symptoms (mMRC 0-1, CAT < 10) receive a single bronchodilator, while those with higher symptoms (mMRC ≥ 2, CAT ≥ 10) receive dual bronchodilator therapy. • The algorithm emphasizes tailored therapy based on risk and symptom burden, with consideration for adherence and convenience.

This set of three axial chest CT scans (lung window) illustrates a progression of treatment for severe emphysematous COPD and persistent pneumothorax. Image A shows a significant left-sided pneumothorax following talc pleurodesis, characterized by an absence of peripheral lung markings and compression of the left lung parenchyma against the mediastinum. Image B, captured one month after left-sided lung volume reduction surgery (LVRS), demonstrates successful resolution of the pneumothorax and re-expansion of the left lung. Although severe bullous emphysema remains visible bilaterally, the mediastinum has shifted from a rightward displacement back toward the midline. Image C shows the thorax one month after a subsequent contralateral (right-sided) LVRS. This final stage reveals improved thoracic symmetry and a further reduction in hyperinflation, with more uniform distribution of the remaining lung parenchyma. The series demonstrates the efficacy of sequential LVRS in managing refractory air leaks and optimizing lung mechanics in patients with end-stage emphysema.

Summary : This figure presents a decision framework for clinicians on when to initiate inhaled corticosteroid (ICS) treatment in patients with COPD who are already on long-acting bronchodilators. It categorizes factors into three groups: those that strongly favor use, favor use, or argue against use of ICS. decision framework: # Strongly Favors Use : • History of hospitalization(s) for exacerbations of COPD. • ≥ 2 moderate exacerbations of COPD per year. • Blood eosinophils ≥ 300 cells/μL. • History of, or concomitant asthma. # Favors Use : • 1 moderate exacerbation of COPD per year. • Blood eosinophils 100 to < 300 cells/μL. # Against Use : • Repeated pneumonia events. • Blood eosinophils < 100 cells/μL. • History of mycobacterial infection. # Design Encodings : • Green box for "Strongly Favors Use". • Yellow box for "Favors Use". • Red box for "Against Use". • Bolded section headings and bullet points for each criterion. • Footnotes clarify that blood eosinophil values are approximate cut-points and may fluctuate, and that recommendations assume appropriate long-acting bronchodilator maintenance therapy. # Analysis : • The figure provides a clear, color-coded decision aid for clinicians, emphasizing that higher exacerbation frequency, higher eosinophil counts, and asthma history favor ICS use, while pneumonia risk, low eosinophil counts, and mycobacterial infection argue against it. The structure supports rapid clinical assessment and stratification of COPD patients for ICS therapy.

This dual-panel image displays diagnostic thoracic imaging from a patient with Chronic Obstructive Pulmonary Disease (COPD). The left panel is a posterior-anterior (PA) chest X-ray showing classic features of severe emphysema, including hyperinflated lung fields, sparse bronchovascular markings, and a widened chest diameter consistent with a barrel chest deformity. Diaphragmatic flattening and a narrowed mediastinal silhouette are also visible. The right panel is an axial CT scan of the chest (lung window) at the level of the upper lobes, revealing extensive bullous emphysema. Multiple large, thin-walled bullae are visible, particularly in the subpleural regions, along with architectural distortion of the lung parenchyma. These findings demonstrate advanced obstructive lung disease and are clinically significant for explaining symptoms of chronic shortness of breath and impaired gas exchange in elderly patients with a significant smoking history.

This clinical photograph provides a lateral view of an elderly male patient in a seated position, demonstrating a classic barrel-shaped chest deformity. This morphological change is characterized by a significant increase in the anterior-posterior (AP) diameter of the thoracic cage, commonly associated with chronic obstructive pulmonary disease (COPD) or severe emphysema. Visible physical findings include significant wasting of the pectoral and shoulder musculature (cachexia) and thin, wrinkled skin over the thorax. A nasal cannula is visible, indicating the need for supplemental oxygen therapy. A square medical dressing is applied to the lateral chest wall, likely at a site following the removal of an intercostal drainage (ICD) tube. The patient exhibits a 'tripod' posture or forward-leaning tendency, which is a common compensatory mechanism used to engage accessory muscles of respiration. A bedside IV pole is visible in the background, suggesting an inpatient clinical setting. This image serves as a teaching tool for physical examination findings in chronic respiratory failure and obstructive lung disease.

This diagnostic image pair displays thoracic radiology findings in an 80-year-old male with Chronic Obstructive Pulmonary Disease (COPD). The left panel shows a frontal chest radiograph (X-ray) exhibiting hallmark signs of hyperinflation, including a widened anteroposterior diameter and flattened diaphragmatic domes. Both lung fields demonstrate sparse bronchovascular markings and increased lucency, indicative of diffuse emphysema. The right panel shows an axial CT scan of the thorax, further characterizing the pulmonary pathology. It reveals significant emphysematous destruction of the lung parenchyma with the presence of multiple bullae and areas of decreased attenuation. Additionally, subtle interstitial lesions are visible. The imaging illustrates the classic presentation of severe COPD, characterized by permanent enlargement of airspaces distal to the terminal bronchioles and associated structural changes to the chest wall often described as a barrel chest.